Kitov Pharmaceuticals Holdings Ltd (NASDAQ:KTOV) shares dropped 3.1% on Monday . The company traded as low as $3.06 and last traded at $3.09, with a volume of 97,114 shares changing hands. The stock had previously closed at $3.19.

KTOV has been the subject of a number of research analyst reports. Zacks Investment Research lowered Kitov Pharmaceuticals Holdings from a “buy” rating to a “hold” rating in a research report on Tuesday, June 28th. Rodman & Renshaw reaffirmed a “buy” rating on shares of Kitov Pharmaceuticals Holdings in a report on Monday, July 11th.

The firm’s market capitalization is $21.00 million. The company’s 50-day moving average price is $3.13 and its 200 day moving average price is $4.07.

An institutional investor recently bought a new position in Kitov Pharmaceuticals Holdings stock. Sabby Management LLC bought a new position in Kitov Pharmaceuticals Holdings Ltd (NASDAQ:KTOV) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 232,524 shares of the company’s stock, valued at approximately $725,000. Sabby Management LLC owned approximately 5.96% of Kitov Pharmaceuticals Holdings at the end of the most recent reporting period.

About Kitov Pharmaceuticals Holdings

Kitov Pharmaceuticals Holdings Ltd is an Israel-based company that develops non-steroidal anti-inflammatory drugs that treat pain without raising blood pressure, thus avoiding the increased risk of heart attacks, strokes or death.

5 Day Chart for NASDAQ:KTOV

Receive News & Ratings for Kitov Pharmaceuticals Holdings Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kitov Pharmaceuticals Holdings Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.